Related Experiment Video
Updated: Sep 19, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.5K
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Toshihide Izumida1,2, Koichiro Kinugawa1
1Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
International Journal of Heart Failure
|June 16, 2025
Summary
New heart failure drugs offer dual protection for the heart and kidneys in patients with chronic kidney disease. These advanced therapies improve outcomes and slow kidney function decline, especially in those with diabetes.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Chronic heart failure (CHF) and chronic kidney disease (CKD) frequently coexist, complicating management and worsening outcomes.
- Managing CHF in advanced CKD is challenging due to standard therapy limitations and dose adjustments.
- Cardiorenal protection is crucial in early disease stages.
Purpose of the Study:
- To review recent advancements in heart failure pharmacotherapy.
- To emphasize the cardiorenal protective mechanisms and clinical efficacy of novel agents.
- To highlight the importance of personalized therapy for optimal cardiorenal benefits.
Main Methods:
- Review of current literature on novel pharmacotherapies for CHF and CKD.
- Analysis of mechanisms of cardiorenal protection offered by specific drug classes.
- Evaluation of clinical trial data on efficacy and safety.
Main Results:
- Novel agents like ARNI, SGLT2 inhibitors, MRA, and GLP-1 RAs show dual cardiorenal protective effects.
- These therapies reduce heart failure risk, improve CHF outcomes, and slow CKD progression.
- Benefits are particularly notable in patients with diabetes, albuminuric CKD, and CHF, despite potential transient GFR dips.
Conclusions:
- Advanced pharmacotherapies offer significant cardiorenal protection in patients with coexisting CHF and CKD.
- Personalized treatment strategies are essential to maximize benefits and minimize adverse effects.
- Further research is needed to bridge knowledge gaps and optimize therapeutic approaches.
Keywords:
Cardio-renal syndromeCardiologyCardiovascular diseasesHeart failureRandomized controlled trialMore Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:22Heart Failure Drugs: Diuretics
505
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
505
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:22Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
01:30Heart Failure VII: Nursing Interventions
147
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
147
01:18Chronic Kidney Disease IV: Nursing Management
62
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
62